

# Polyphenols in beer: the role of xanthohumol and isoxanthohumol

Rosa M. Lamuela  
University of Barcelona



*Beer and Health*

THE 7<sup>TH</sup> EUROPEAN  
BEER AND HEALTH SYMPOSIUM



# Index

- What are polyphenols
- Polyphenols and health outcomes
- Polyphenols from beer
- Health effects of prenylflavonoids from beer



In 1991, key word: polyphenols  
Only 23 papers about:

Antioxidant  
effects *in vitro*

Presence in food

Antitumoral  
properties

On September 26 2014, Key word: polyphenols  
1318 papers in 12 months

Apoptosis

Arthritis

Inflammation

Effect on  
testosterone

Antibactericide


Cosmoceutical

...



# Polyphenols

Nowadays they are not considered **nutrients** however they are bioactive compounds, since they perform important physiological functions in the organism.




Chiou, Y.-S. *et al.* 2014

# Index


- What are polyphenols
- **Polyphenols and health outcomes**
- Polyphenols from beer
- Health effects of prenylflavonoids from beer
- Isoxanthohumol reliable biomarker of beer consumption



# Polyphenols and Cardiovascular Health



**7447**  
**55-80 years**  
**Free of CVD but at high risk**



502 polyphenols in 452 foods



*Beer and Health*



# Polyphenol Intake and Cardiovascular

Nutrition, Metabolism & Cardiovascular Diseases (2014) xx, 1–9




ELSEVIER

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

Nutrition, Metabolism & Cardiovascular Diseases

journal homepage: [www.elsevier.com/locate/nmcd](http://www.elsevier.com/locate/nmcd)



## Inverse association between habitual polyphenol intake and incidence of cardiovascular events in the PREDIMED study

A. Tresserra-Rimbau<sup>a,b</sup>, E.B. Rimm<sup>c,d</sup>, A. Medina-Remón<sup>a,b</sup>,  
M.A. Martínez-González<sup>b,e</sup>, R. de la Torre<sup>b,f</sup>, D. Corella<sup>b,g</sup>, J. Salas-Salvadó<sup>b,h</sup>,  
E. Gómez-Gracia<sup>b,i</sup>, J. Lapetra<sup>b,j</sup>, F. Arós<sup>b,k</sup>, M. Fiol<sup>b,l</sup>, E. Ros<sup>b,m</sup>, L. Serra-Majem<sup>b,n</sup>,  
X. Pintó<sup>b,o</sup>, G.T. Saez<sup>b,p</sup>, J. Basora<sup>b,q</sup>, J.V. Sorlí<sup>b,r</sup>, J.A. Martínez<sup>b,s</sup>, E. Vinyoles<sup>b,t</sup>,  
V. Ruiz-Gutiérrez<sup>b,u</sup>, R. Estruch<sup>b,v</sup>, R.M. Lamuela-Raventós<sup>a,b,\*</sup> on behalf of the  
PREDIMED Study Investigators



Beer and Health

# POLYPHENOLS AND CARDIOVASCULAR HEALTH

**Table 2** Association between quintiles of cumulative polyphenol intake (total and main groups) and incident CVD in the PREDIMED study.

	Q1	Q2	Q3	Q4	Q5	P for trend
<b>Total polyphenols (mg/d)</b>	562	701	800	917	1170	
No. of CVD cases	66	49	58	49	51	
No. of person years	5312	6668	6905	6629	5554	
Age and sex adjusted	1.00	0.60 (0.38–0.95) <sup>a</sup>	0.62 (0.39–0.97)	0.58 (0.36–0.91)	0.58 (0.36–0.93)	0.04
Model 2 <sup>b</sup>	1.00	0.57 (0.36–0.92)	0.60 (0.38–0.95)	0.54 (0.34–0.87)	0.51 (0.30–0.84)	0.02

**Table 2** Association between quintiles of cumulative polyphenol intake (total and main groups) and incident CVD in the PREDIMED study.

	Q1	Q2	Q3	Q4	Q5	P for trend
<b>Total polyphenols (mg/d)</b>	562	701	800	917	1170	
No. of CVD cases	66	49	58	49	51	
No. of person years	5312	6668	6905	6629	5554	
Age and sex adjusted	1.00	0.60 (0.38–0.95) <sup>a</sup>	0.62 (0.39–0.97)	0.58 (0.36–0.91)	0.58 (0.36–0.93)	0.04
Model 2 <sup>b</sup>	1.00	0.57 (0.36–0.92)	0.60 (0.38–0.95)	0.54 (0.34–0.87)	0.51 (0.30–0.84)	0.02
Model 3 <sup>c</sup>	1.00	0.60 (0.38–0.97)	0.67 (0.42–1.07)	0.59 (0.37–0.96)	0.54 (0.33–0.91)	0.04
No. of person years	5341	6541	6640	6491	6055	
Age and sex	1.00	0.64 (0.40–1.04)	0.81 (0.52–1.27)	0.65 (0.42–1.02)	0.66 (0.42–1.04)	0.22
Model 2	1.00	0.94 (0.46–1.95)	1.17 (0.55–2.47)	0.96 (0.46–2.00)	0.69 (0.31–1.56)	0.19

<b>Lignans (mg/d)</b>	0.44	0.57	0.67	0.77	0.94	
No. of cases	69	57	53	44	50	
No. of person years	4625	6122	6899	6892	6530	
Age and sex	1.00	0.61 (0.40–0.95)	0.55 (0.36–0.86)	0.57 (0.35–0.91)	0.51 (0.31–0.84)	0.004
Model 2	1.00	0.65 (0.41–1.01)	0.55 (0.35–0.87)	0.61 (0.37–0.99)	0.50 (0.29–0.85)	0.007
Model 3	1.00	0.64 (0.41–0.99)	0.54 (0.34–0.85)	0.60 (0.36–0.97)	0.51 (0.30–0.86)	0.007
Age and sex	1.00	1.00 (0.65–1.55)	0.88 (0.55–1.39)	0.75 (0.46–1.21)	0.67 (0.40–1.11)	0.06
Model 2	1.00	0.97 (0.62–1.53)	0.86 (0.53–1.37)	0.70 (0.43–1.15)	0.63 (0.38–1.05)	0.02
Model 3	1.00	1.08 (0.69–1.71)	0.94 (0.58–1.53)	0.84 (0.51–1.38)	0.74 (0.43–1.26)	0.14

<sup>a</sup> HR (95% CI).

<sup>b</sup> Additionally adjusted for smoking, BMI, alcohol, physical activity, family history of CVD, aspirin use, antihypertensive drugs, cardiovascular drugs, diabetes status, and total energy intake.

<sup>c</sup> Additionally adjusted for intake of protein, saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, and cholesterol.



# FLAVONOIDS AND CARDIOVASCULAR HEALTH

**Table 3** The relationship between CVD and cumulative flavonoids subclasses intake (in quintiles) in participants from the PREDIMED study.

Flavonoids	Q1	Q2	Q3	Q4	Q5	P for trend
<b>Anthocyanins (mg/d)</b>	11.8	23.6	32.8	45.7	74.6	
No. of cases	69	57	52	43	52	
No. of person years	5375	6347	6589	6963	5795	

<b>Anthocyanins (mg/d)</b>	11.8	23.6	32.8	45.7	74.6	
No. of cases	69	57	52	43	52	
No. of person years	5375	6347	6589	6963	5795	
Age and sex	1.00	0.95 (0.65–1.40) <sup>a</sup>	0.62 (0.41–0.94)	0.52 (0.34–0.80)	0.60 (0.39–0.90)	0.004
Model 2 <sup>b</sup>	1.00	1.15 (0.74–1.79)	0.82 (0.51–1.33)	0.65 (0.39–1.09)	0.62 (0.36–1.06)	0.03
Model 3 <sup>c</sup>	1.00	1.18 (0.76–1.84)	0.85 (0.52–1.38)	0.67 (0.40–1.11)	0.67 (0.39–1.13)	0.05
<b>Dihydrochalcones (mg/d)</b>	0.8	1.8	2.6	3.5	5.8	
No. of cases	47	59	55	57	55	
No. of person years	5036	6268	7563	5524	6677	
Age and sex	1.00	1.11 (0.73–1.67)	0.92 (0.60–1.40)	0.96 (0.62–1.48)	0.62 (0.39–0.99)	0.02
Model 2	1.00	1.25 (0.78–1.99)	0.90 (0.55–1.46)	0.92 (0.56–1.52)	0.61 (0.35–1.05)	0.02
Model 3	1.00	1.24 (0.78–1.99)	0.92 (0.56–1.50)	0.95 (0.57–1.57)	0.63 (0.36–1.08)	0.03

Model 2	1.00	0.65 (0.41–1.02)	0.70 (0.44–1.09)	0.57 (0.36–0.91)	0.36 (0.20–0.63)	0.0004
Model 3	1.00	0.70 (0.44–1.10)	0.77 (0.49–1.21)	0.66 (0.41–1.05)	0.40 (0.23–0.72)	0.003
<b>Flavanones (mg/d)</b>	28	78	113	157	247	
No. of cases	50	51	49	55	68	

<b>Flavanols (mg/d)</b>	90	129	158	192	263	
No. of cases	69	51	59	59	35	
No. of person years	4841	6409	7058	6860	5900	
Age and sex	1.00	0.64 (0.43–0.94)	0.65 (0.44–0.95)	0.55 (0.37–0.82)	0.33 (0.21–0.53)	<0.0001
Model 2	1.00	0.65 (0.41–1.02)	0.70 (0.44–1.09)	0.57 (0.36–0.91)	0.36 (0.20–0.63)	0.0004
Model 3	1.00	0.70 (0.44–1.10)	0.77 (0.49–1.21)	0.66 (0.41–1.05)	0.40 (0.23–0.72)	0.003

Model 3	1.00	0.94 (0.56–1.56)	1.37 (0.83–2.27)	1.30 (0.79–2.12)	1.07 (0.64–1.80)	0.72
<b>Flavonols (mg/d)</b>	56	74	88	101	124	
No. of cases	69	57	55	40	52	
No. of person years	5608	6961	6668	6179	5652	
Age and sex	1.00	0.85 (0.58–1.25)	0.63 (0.42–0.95)	0.44 (0.28–0.70)	0.56 (0.35–0.88)	0.002
Model 2	1.00	0.79 (0.51–1.22)	0.69 (0.44–1.09)	0.48 (0.28–0.80)	0.58 (0.34–0.98)	0.02
Model 3	1.00	0.84 (0.54–1.31)	0.74 (0.46–1.17)	0.53 (0.31–0.90)	0.69 (0.40–1.19)	0.08

<sup>a</sup> HR (95% CI).

<sup>b</sup> Model 2 – age, sex, smoking, BMI, alcohol, energy, physical activity, family history of CVD, aspirin use, antihypertensive drugs, cardiovascular drugs, and diabetes status.

<sup>c</sup> Model 3 – model 2 plus intake of proteins, saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, and cholesterol.



# PHENOLIC ACIDS AND CARDIOVASCULAR HEALTH

**Table 4** The relationship between CVD and cumulative phenolic acids subclasses intake (in quintiles) in participants from the PREDIMED study.

Phenolic acids	Q1	Q2	Q3	Q4	Q5	<i>P</i> for trend
<b>Hydroxybenzoic acids (mg/d)</b>	6.9	12.9	17.8	24.1	36.1	
No. of cases	69	62	47	55	40	
No. of person years	5398	6603	6734	6853	5480	
Age and sex	1.00	0.80 (0.54–1.17) <sup>a</sup>	0.60 (0.40–0.90)	0.54 (0.36–0.82)	0.46 (0.29–0.71)	0.0003
Model 2 <sup>b</sup>	1.00	0.82 (0.52–1.29)	0.65 (0.40–1.06)	0.59 (0.36–0.97)	0.37 (0.20–0.66)	0.0006
Model 3 <sup>c</sup>	1.00	0.91 (0.57–1.43)	0.74 (0.46–1.22)	0.73 (0.44–1.21)	0.47 (0.26–0.86)	0.02
<b>Hydroxycinnamic acids (mg/d)</b>	138	207	252	316	422	
No. of cases	61	50	42	59	61	
No. of person years	5632	6486	6869	6914	5167	
Age and sex	1.00	0.80 (0.53–1.20)	0.55 (0.35–0.87)	0.92 (0.62–1.36)	1.08 (0.72–1.63)	0.40
Model 2	1.00	0.81 (0.51–1.29)	0.57 (0.34–0.96)	0.91 (0.58–1.42)	0.99 (0.62–1.58)	0.71
Model 3	1.00	0.79 (0.49–1.25)	0.58 (0.35–0.97)	0.86 (0.55–1.36)	0.93 (0.58–1.49)	0.93
<b>Other phenolic acids (mg/d)</b>	0.1	2.5	4.6	8.6	17.9	
No. of cases	58	66	47	62	40	
No. of person years	5100	5225	6571	7787	5385	
Age and sex	1.00	1.11 (0.75–1.64)	0.69 (0.45–1.08)	0.79 (0.52–1.21)	0.73 (0.46–1.14)	0.10
Model 2	1.00	1.31 (0.83–2.09)	0.75 (0.44–1.28)	0.88 (0.54–1.42)	0.74 (0.45–1.24)	0.11
Model 3	1.00	1.39 (0.87–2.22)	0.82 (0.48–1.39)	0.92 (0.57–1.51)	0.82 (0.49–1.39)	0.19

<sup>a</sup> HR (95% CI).

<sup>b</sup> Model 2 – age, sex, smoking, BMI, alcohol, energy, physical activity, family history of CVD, aspirin use, antihypertensive drugs, cardiovascular drugs, and diabetes status.

<sup>c</sup> Model 3 – model 2 plus intake of proteins, saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, and cholesterol.



Tresserra-Rimbau *et al. BMC Medicine* 2014, 12:77  
<http://www.biomedcentral.com/1741-7015/12/77>



RESEARCH ARTICLE


Open Access

## Polyphenol intake and mortality risk: a re-analysis of the PREDIMED trial

Anna Tresserra-Rimbau<sup>1,2</sup>, Eric B Rimm<sup>3</sup>, Alexander Medina-Remón<sup>2,17</sup>, Miguel A Martínez-González<sup>2,4</sup>, M Carmen López-Sabater<sup>1,2</sup>, María I Covas<sup>2,5</sup>, Dolores Corella<sup>2,6</sup>, Jordi Salas-Salvadó<sup>2,7</sup>, Enrique Gómez-Gracia<sup>2,8</sup>, José Lapetra<sup>2,9</sup>, Fernando Arós<sup>2,10</sup>, Miquel Fiol<sup>2,11</sup>, Emili Ros<sup>2,12</sup>, Lluís Serra-Majem<sup>2,13</sup>, Xavier Pintó<sup>2,14</sup>, Miguel A Muñoz<sup>2,15</sup>, Alfredo Gea<sup>2,4</sup>, Valentina Ruiz-Gutiérrez<sup>2,16</sup>, Ramón Estruch<sup>2,17</sup>, Rosa M Lamuela-Raventós<sup>1,2\*</sup>  
and on behalf of the PREDIMED Study Investigators



# Polyphenol Intake and Mortality Risk



# Polyphenol Intake and Mortality Risk

**Table 2 Cox proportional hazard ratios for total mortality according to quintiles of cumulative total polyphenol intake**

	Quintiles of cumulative intake of total polyphenols, mg/d					P-trend
	Q1 (535)	Q2 (700)	Q3 (800)	Q4 (917)	Q5 (1170)	
No. of deaths	88	62	52	63	62	
No. of person-years	5,505	6,599	6,767	6,559	5,638	
Age- and sex-adjusted HR (95% CI)*	1.00	0.65 (0.44 to 0.95)	0.55 (0.37 to 0.82)	0.73 (0.50 to 1.06)	0.66 (0.44 to 0.98)	0.12
Multivariable-adjusted HR (95% CI)†	1.00	0.68 (0.46 to 1.01)	0.60 (0.39 to 0.90)	0.75 (0.51 to 1.12)	0.60 (0.39 to 0.91)	0.07
Additionally adjusted HR (95% CI)‡	1.00	0.71 (0.48 to 1.05)	0.62 (0.41 to 0.95)	0.79 (0.53 to 1.17)	0.63 (0.41 to 0.97)	0.12

HR, Hazard ratio; CI, Confidence interval.

\*Analyses were stratified by sex, recruitment center and intervention group.

†The multivariable HR has been additionally adjusted for age (<60, 60 to 64.9, 65 to 69.9, 70 to 74.9, ≥75 years), smoking (never, past and current: cigarettes (<5, 5 to 19, ≥20 per day) or cigars and pipes (<3, 3 to 6, ≥6 per day)), BMI (<25, 25 to 29.9, or ≥30 Kg/m<sup>2</sup>), baseline diabetes, alcohol (0, 0.1 to 14.9, 15 to 29.9, ≥30 g/day), total energy intake (continuous variable), physical activity (continuous variable), family history of CVD or cancer, aspirin use, antihypertensive drug use, use of cardiovascular medication, use of oral hypoglycaemic agents, insulin, other medication.


‡This model has been additionally adjusted for intake of protein, saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids and cholesterol (all as continuous variables).

Total polyphenol intake was significantly associated with a decrease (almost 40%) in all-cause mortality, after adjusting for all confounders. The dose-response trend suggested an L-shaped relationship.





# Polyphenol Intake and Mortality Risk



Hazard ratios (95% CI) of total mortality for the highest vs. lowest quintiles of polyphenol intake.

## Isoflavones

HR 0.49; CI 0.28 to 0.84; P-trend=0.009

## Stilbenes

HR 0.48; CI 0.25 to 0.91; P-trend=0.04

## Lignans


HR 0.60; CI 0.37 to 0.95; P-trend=0.03

# Index

- What are polyphenols
- Polyphenols and health outcomes
- **Polyphenols from beer**
- Health effects of prenylflavonoids from beer



# Beer Polyphenols by LC-LTQ-Orbitrap MS



- We analyzed the beer polyphenolic profile by High Resolution Mass Spectrometry (LC-LTQ-Orbitrap)
- 3 types of Beer: Marzen Bier, Pilsen and Lager.
- Full Scan Mode and Tandem MS/MS experiments with accurate mass measurements of the ions and the fragments
- **47 phenolic compounds were detected, 7 of them were reported for the first time**




# Malt Polyphenols

70-80% of the beer polyphenols come from malt


## Hydroxybenzoic acids

Gallic acid  
Protocatechuic acid-*O*-hexoside  
Dihydroxybenzoic acid  
Protocatechuic acid  
Hydroxybenzoic acid  
Vanillic acid



## Alkylmethoxyphenols

4-vinylguaiaicol



## Hydroxycinnamic acids

Caffeic acid *O*-hexoside

Caffeic acid  
1-caffeoylquinic acid  
3-caffeoylquinic acid  
4-caffeoylquinic acid  
5-caffeoylquinic acid


Coumaric acid *O*-hexoside

Feruloylquinic acid

Sinapic acid-*O*-hexoside


Sinapic acid

Ferulic acid



## Hydroxyphenylacetic acids


Hydroxyphenylacetic acid



# Malt Polyphenols


## Flavanols

Catechin  
Catechin-*O*-hexoside  
Catechin-*O*-dihexoside  
Epicatechin




## Miscellaneous

Indole-3-carboxylic  
acid




## Flavonols

Quercetin-3-*O*-glucoside  
Kaempferol-*O*-hexoside  
3,7-dimethylquercetin



## Flavones

Apigenin-*C*-hexoside-*O*-hexoside  
Apigenin-*C*-hexoside-pentoside  
Apigenin-*C*-hexoside






# Hop Polyphenols

**30-20% of the  
beer polyphenols  
come from hops**


## **$\alpha$ -acids and $\beta$ -acids**

co-Humulone  
ad-Humulone  
n-Humulone  
Iso- $\alpha$ -cohumulone  
Iso- $\alpha$ -adhumulone  
Iso- $\alpha$ -nhumulone  
Lupulone




## **Prenylflavanoids**

Isoxanthohumol  
Xanthohumol  
Desmethyloxanthohumol  
8-prenylnaringenin  
6-prenylnaringenin



# Polyphenol Intake from one Drink



92 mg

330 mL



48 mg

150 mL




300 mg

150 mL



# Beer and Wine: a Metanalisi



Reduction of cardiovascular risk

- Wine: -32%
- Beer: -22%

*Circulation 2002*




# Index

- What are polyphenols
- Polyphenols and health outcomes
- Polyphenols from beer
- Health effects of prenylflavonoids from beer




# Prenylflavanoids



95% of the prenylflavanoids found in hops are xanthohumol, desmethylxanthohumol, and 3-geranylchalconenaringenina. (Stevens et al, 1999)



High content in isoxanthohumol (prenylflavanone) and low content in xanthohumol (Stevens et al 1999)



Isoxanthohumol is converted to 8-prenylnaringenin by an O-desmethylation catalyzed by gut microbiota. (Hanske L et al 2010, Possemiers S et al 2005)





## 8-prenylnaringenin

- Most potent phytoestrogen known until date. It showed similar binding characteristics to ER $\alpha$  and ER $\beta$  *in vitro*. The oestrogenic activity of 8-prenylnaringenin was greater than that of established phyto-oestrogens such as coumestrol, genistein and daidzein. (Milligan et al. 2000)
- Owing to this phytoestrogenic activity, 8PN has been proposed as a treatment for menopausal symptoms, such as hot flashes and osteoporosis

238

S. Milligan et al.




Fig. 2. Relative oestrogenic activity of oestradiol (●), 8-prenylnaringenin (semi-synthetic; ○), 8-prenylnaringenin (natural; ▼) and other phyto-oestrogens (coumestrol (▽), genistein (■), daidzein (□)) in (a) Ishikawa Var I cells and (b) yeast screen bearing the human oestrogen receptor. Results are means  $\pm$  SEM;  $n = 6$  wells per point. Where no error bars are visible, the errors were smaller than the symbols.



# Biological Activity of Beer Prenylflavanoids

## Xanthohumol and Isoxanthohumol

- Xanthohumol and isoxanthohumol have shown weak or no estrogenic activity.
- IX is considered to be a source of 8-prenylnaringenin, because it is metabolized to 8-prenylnaringenin in the intestinal tract by gut microbiota.



# Urinary Isoxanthohumol as a Biomarker of Beer Consumption



The Journal of Nutrition  
**Nutritional Epidemiology**

J. Nutr. 144: 484–488, 2014.

## **Urinary Isoxanthohumol Is a Specific and Accurate Biomarker of Beer Consumption<sup>1–3</sup>**

Paola Quifer-Rada,<sup>4,5</sup> Miriam Martínez-Huélamo,<sup>4,5</sup> Gemma Chiva-Blanch,<sup>5,6</sup> Olga Jáuregui,<sup>7</sup> Ramon Estruch,<sup>5,6</sup> and Rosa M. Lamuela-Raventós<sup>4,5\*</sup>

<sup>4</sup>Department of Nutrition and Food Science-XARTA-INSA, School of Pharmacy, University of Barcelona, Barcelona, Spain; <sup>5</sup>CIBER Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain; and <sup>6</sup>Department of Internal Medicine, Hospital Clínic, Institute of Biomedical Investigation August Pi i Sunyer, and <sup>7</sup>Scientific and Technological Center, University of Barcelona, Barcelona, Spain




*Beer and Health*





# Urinary Isoxanthohumol as a Biomarker of Beer Consumption

Dose-response, randomized,  
cross-over clinical trial




# Urinary excretion of Isoxanthohumol in male (A) and female (B) volunteers 8 hours after the intake of different volumes of beer






# In Free Living Population in PREDIMED



IX is really a good boomarker that can be used in epidemiological studies to evaluate beer health outcomes.



Beer and Health

# Conclusions

- Polyphenols consumption decrease all cause of mortality and CVD
- Beer has been shown to be a good source of polyphenols and it is one of the main food contributor to hydroxybenzoic acid intake in the European Prospective Investigation into Cancer and Nutrition cohort study.
- High intake of hydroxybenzoics decrease cardiovascular risk by 53% in the PREDIMED population
- IX is a good biomarker that may be used in epidemiological studies to evaluate beer health outcomes



We would like to thank:



Beer and Health

THE 7<sup>TH</sup> EUROPEAN

BEER AND HEALTH SYMPOSIUM







**Visit our web site:**

**Group director** Rosa M<sup>a</sup> Lamuela Raventós

**Board Committee** Ramón estruch Riba

**<http://www.polyphenolresearch.com>**

**Predoctoral researchers**

Miriam Martínez	Mariel Colman	Gemma Sasot	Naiara Orrego
Anna Tresserra	Paola Quifer	Guao Xiao Hui	Ana Barrionuevo Anna Creus

**Collaborators**

Mónica Vázquez	Montse Illán	Xavier Torrado
----------------	--------------	----------------



THANK YOU  
[lamuela@ub.edu](mailto:lamuela@ub.edu)